Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms
Marceau Quatredeniers,
Pedro Mendes-Ferreira,
Diana Santos-Ribeiro,
Morad K. Nakhleh,
Maria-Rosa Ghigna,
Sylvia Cohen-Kaminsky,
Frédéric Perros
Affiliations
Marceau Quatredeniers
INSERM UMR_S 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
Pedro Mendes-Ferreira
Cardiovascular R&D Center, Faculty of Medicine of the University of Porto, 4200-450 Porto, Portugal
Diana Santos-Ribeiro
Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology, Université catholique de Louvain (UCL), 1060 Brussels, Belgium
Morad K. Nakhleh
INSERM UMR_S 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
Maria-Rosa Ghigna
INSERM UMR_S 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
Sylvia Cohen-Kaminsky
INSERM UMR_S 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
Frédéric Perros
INSERM UMR_S 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
Pulmonary arterial hypertension (PAH) is a severe cardiovascular disease that is caused by the progressive occlusion of the distal pulmonary arteries, eventually leading to right heart failure and death. Almost 40% of patients with PAH are iron deficient. Although widely studied, the mechanisms linking between PAH and iron deficiency remain unclear. Here we review the mechanisms regulating iron homeostasis and the preclinical and clinical data available on iron deficiency in PAH. Then we discuss the potential implications of iron deficiency on the development and management of PAH.